Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
GFH-312 by GenFleet Therapeutics (Shanghai) for Autoimmune Disorders: Likelihood of Approval
GFH-312 is under clinical development by GenFleet Therapeutics (Shanghai) and currently in Phase II for Autoimmune Disorders. According to GlobalData,...